论文检索
期刊
全部知识仓储预印本开放期刊机构
高级检索

SLC2A1在肝细胞癌中的表达及其临床意义OA北大核心CSTPCD

Expression of SLC2A1 in hepatocellular carcinoma and its clinical significance

中文摘要英文摘要

背景与目的:溶质载体家族2成员1(SLC2A1)基因编码的葡萄糖转运蛋白1(GLUT1)与糖酵解途径密切相关,而糖酵解是恶性肿瘤供能的主要生理途径,因此,SLC2A1可能与多种恶性肿瘤的发生发展有关.鉴于SLC2A1在肝细胞癌(HCC)中的表达及生物学功能并不完全清楚,本研究通过生物信息学方法和临床研究探讨SLC2A1在HCC中的表达及意义. 方法:从癌症基因组图谱数据库(TCGA)下载HCC患者的RNA-seq数据与临床信息,分析SLC2A1在HCC中的表达、预后价值,以及对不同SLC2A1表达水平HCC患者差异表达基因做富集分析和相关性分析.收集江苏省苏北人民医院80例临床HCC患者的手术标本与临床病理资料,分析SLC2A1在HCC中的表达情况,以及SLC2A1表达水平与患者临床病理特征、预后的关系,并筛选影响患者预后的独立危险因素. 结果:TCGA数据库分析结果显示,SLC2A1 mRNA在HCC中高表达,并且高表达患者的总生存期(HR=2.50,95%CI=1.76~3.56,P<0.001)、疾病特异性生存期(HR=2.13,95%CI=1.34~3.37,P=0.001)和无复发间期(HR=1.42,95%CI=1.05~1.93,P=0.025)均明显差于低表达患者;其表达水平与RNA甲基化、免疫细胞浸润程度有关(均P<0.05).80例患者临床病理资料的比较分析结果显示,SLC2A1蛋白在HCC组织中的表达明显高于癌旁组织(P<0.05);SLC2A1表达水平与TNM分期、乙型病毒性肝炎和血管侵犯明显有关(均P<0.05).单因素分析显示,TNM分期(HR=1.921,95%CI=1.365~1.554,P-0.01)、血管侵犯(HR=1.925,95%CI=1.253~2.958,P=0.003)、乙型病毒性肝炎(HR=1.365,95%CI=0.624~1.654,P=0.029),甲胎蛋白(HR=1.629,95%CI=1.063~2.479,P=0.025)和 SLC2A1(HR=1.934,95%CI=1.261~2.965,P=0.002)与患者预后有关,多因素分析表明,血管侵犯(HR=1.657,95%CI=1.036~2.652,P=0.035)和 SLC2A1(HR=1.753,95%CI=1.132~2.715,P=0.012)是 HCC 患者预后的独立危险因素. 结论:SLC2A1在HCC中高表达,其高表达与患者不良预后密切相关.SLC2A1除了具有参与糖酵解功能外,还可能具有多种生物学功能,对其进一步研究有望为HCC的防治及预后评估找到新的靶点.

Background and Aims:The gene solute carrier family 2 member 1(SLC2A1)encodes the glucose transporter 1(GLUT1),which is closely related to the glycolysis pathway.Glycolysis is a primary physiological pathway for energy supply in malignant tumors.Therefore,SLC2A1 may be involved in the occurrence and development of various malignant tumors.Given that the expression and biological function of SLC2A1 in hepatocellular carcinoma(HCC)are not fully understood,this study was conducted to investigate the expression and significance of SLC2A1 in HCC through bioinformatics methods and clinical research. Methods:The RNA-seq data and clinical information of HCC patients were downloaded from the TCGA database.The expression of SLC2A1 in HCC,its prognostic value,and the differentially expressed genes in HCC patients with different levels of SLC2A1 expression were analyzed through enrichment and correlation analysis.Surgical specimens and clinicopathologic data from 80 HCC patients treated at Northern Jiangsu People's Hospital were collected.The expression of SLC2A1 in HCC and its relationship with clinicopathologic characteristics and prognosis were analyzed.Independent risk factors affecting the prognosis of patients were also screened. Results:The analysis of the TCGA database showed that SLC2A1 mRNA was highly expressed in HCC.Patients with high expression had significantly worse overall survival(HR=2.50,95%CI=1.76-3.56,P<0.001),disease-specific survival(HR=2.13,95%CI=1.34-3.37,P=0.001),and recurrence-free survival(HR=1.42,95%CI=1.05-1.93,P=0.025)compared to those with low expression.The expression level of SLC2A1 was closely related to RNA methylation and the degree of immune cell infiltration(all P<0.05).Comparative analysis of clinical pathological data from 80 patients showed that the expression of SLC2A1 protein in HCC tissues was significantly higher than in adjacent non-tumor tissues(P<0.05).SLC2A1 expression level was significantly associated with TNM stage,hepatitis B infection,and vascular invasion(all P<0.05).Univariate analysis showed that TNM stage(HR=1.921,95%CI=1.365-1.554,P=0.01),vascular invasion(HR=1.925,95%CI=1.253-2.958,P=0.003),hepatitis B infection(HR=1.365,95%CI=0.624-1.654,P=0.029),alpha-fetoprotein(HR=1.629,95%CI=1.063-2.479,P=0.025),and SLC2A1(HR=1.934,95%CI=1.261-2.965,P=0.002)were associated with patient prognosis.Multivariate analysis indicated that vascular invasion(HR=1.657,95%CI=1.036-2.652,P=0.035)and SLC2A1(HR=1.753,95%CI=1.132-2.715,P=0.012)were independent risk factors for the prognosis of HCC patients. Conclusion:SLC2A1 is highly expressed in HCC,and its high expression is closely related to poor prognosis in patients.Besides its role in glycolysis,SLC2A1 may have various biological functions.Further research on SLC2A1 may potentially identify new targets for the prevention,treatment,and prognostic evaluation of HCC.

陈勇治;柏斗胜

江苏省苏北人民医院/扬州大学附属苏北人民医院肝胆外科,江苏扬州 225009

临床医学

癌,肝细胞;葡萄糖转运体1型;预后;计算生物学

Carcinoma,Hepatocellular;Glucose Transporter Type 1;Prognosis;Computational Biology

《中国普通外科杂志》 2024 (007)

1059-1069 / 11

国家自然科学基金资助项目(82373034).

10.7659/j.issn.1005-6947.2024.07.005

评论

下载量:0
点击量:0